Lonza Group AG (LZAGY)
| Market Cap | 43.39B -6.7% |
| Revenue (ttm) | 8.24B -1.6% |
| Net Income | -346.81M |
| EPS | -4.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 26.36 |
| Dividend | 0.30 (0.48%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 95,612 |
| Average Volume | 67,342 |
| Open | 61.58 |
| Previous Close | 62.09 |
| Day's Range | 61.58 - 62.58 |
| 52-Week Range | 58.53 - 73.85 |
| Beta | 0.82 |
| RSI | 47.30 |
| Earnings Date | Jul 22, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanc... [Read more]
News
Simulations Plus enters funded research collaboration with Lonza, FDA
Simulations Plus (SLP) announced a funded research collaboration with Lonza Group (LZAGY) and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for asse...
Lonza price target lowered to CHF 630 from CHF 680 at Berenberg
Berenberg lowered the firm’s price target on Lonza (LZAGY) to CHF 630 from CHF 680 and keeps a Buy rating on the shares.
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the ...
RBC upgrades Lonza to Outperform, sees ‘higher-quality business’
As previously reported, RBC Capital analyst Charles Weston upgraded Lonza (LZAGY) to Outperform from Sector Perform with a price target of CHF 670, up from CHF 630. Lonza’s growth “algorithm”
Lonza upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Lonza (LZAGY) to Outperform from Sector Perform.
Lonza price target lowered to CHF 695 from CHF 753 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Lonza (LZAGY) to CHF 695 from CHF 753 and keeps a Buy rating on the shares. Published first on
Lonza upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin upgraded Lonza (LZAGY) to Overweight from Equal Weight with a price target of SEK 650, up from SEK 625. Current share levels offer an attractive
Lonza price target raised to CHF 675 from CHF 650 at JPMorgan
JPMorgan raised the firm’s price target on Lonza (LZAGY) to CHF 675 from CHF 650 and keeps an Overweight rating on the shares.
Lonza price target raised to CHF 753 from CHF 744 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Lonza (LZAGY) to CHF 753 from CHF 744 and keeps a Buy rating on the shares.
Lonza initiated with an Outperform at BNP Paribas Exane
BNP Paribas Exane analyst Odysseas Manesiotis initiated coverage of Lonza (LZAGY) with an Outperform rating and CHF 705 price target The company’s exposure is geared toward high growth niches, enablin...
Lonza price target lowered to CHF 630 from CHF 640 at RBC Capital
RBC Capital lowered the firm’s price target on Lonza (LZAGY) to CHF 630 from CHF 640 and keeps a Sector Perform rating on the shares.
Lonza price target lowered to CHF 670 from CHF 710 at Barclays
Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the shares.
Lonza price target raised to CHF 640 from CHF 610 at RBC Capital
RBC Capital raised the firm’s price target on Lonza (LZAGY) to CHF 640 from CHF 610 and keeps a Sector Perform rating on the shares.
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin downgraded Lonza (LZAGY) to Equal Weight from Overweight with a CHF 625 price target The stock’s valuation is the high end of the historical range,
Lonza price target raised to CHF 710 from CHF 630 at Barclays
Barclays raised the firm’s price target on Lonza (LZAGY) to CHF 710 from CHF 630 and keeps an Overweight rating on the shares.
Lonza price target raised to CHF 744 from CHF 645 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Lonza (LZAGY) to CHF 744 from CHF 645 and keeps a Buy rating on the shares.
Lonza price target raised to CHF 680 from CHF 640 at Berenberg
Berenberg analyst Sebastian Bray raised the firm’s price target on Lonza (LZAGY) to CHF 680 from CHF 640 and keeps a Buy rating on the shares.
Rapid Micro Biosystems announces QC solution collaboration with Lonza
Rapid Micro Biosystems (RPID) announced a collaboration with Lonza (LZAGY) integrating the Growth Direct and Lonza’s MODA-EM module, creating the first fully automated end-to-end environmental monitor...
Illumina enters licensing agreement with Lonza
Synaffix B.V., a Lonza (LZAGY) company, announced it has entered into a licensing agreement with Illumina (ILMN). The agreement grants Illumina access to Synaffix’s patented metal-free click chemistry...
Lonza price target raised to CHF 650 from CHF 645 at JPMorgan
JPMorgan analyst Richard Vosser raised the firm’s price target on Lonza (LZAGY) to CHF 650 from CHF 645 and keeps an Overweight rating on the shares.
LZAGY, DSDVY: Investment Opportunities Outside of the U.S.
U.S. equity markets have benefitted from a perceived quality advantage over Europe, though it's uncertain when outperformance will end, notes Bryan Lee. He discusses finding investment opportunities o...
Lonza chairman to step down, drugmaker confirms targets, shares soar
Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples ...
Lonza CEO departure prompts concern over earnings prospects
Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about th...
10 Solid Stocks WIth Terrible Tickers
Stocks with long symbols are difficult to remember and easy to overlook. That would be a mistake.
Lonza's first-half core EBITDA gains 16.5%
Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from drugmakers.